Skip to main
MTVA
MTVA logo

MTVA Stock Forecast & Price Target

MTVA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MetaVia Inc. is demonstrating promising clinical results with its leading candidate, DA-1726, a novel dual agonist for obesity, which has shown an average reduction in fasting glucose levels of 5.3 mg/dL, with some cases reaching reductions as high as 18 mg/dL within just two days. Additionally, the treatment has led to a significant reduction in waist circumference, averaging 1.6 inches from a baseline of 41 inches, and achieving a maximum decrease of 3.9 inches by Day 33. Importantly, DA-1726 has shown a maximum body weight loss of 6.3% from baseline with a mean loss of 4.3% at Day 26, indicating sustained efficacy without signs of plateauing, which could enhance MetaVia's market potential for treating cardiometabolic diseases.

Bears say

MetaVia Inc faces several significant risks impacting its investment outlook, primarily stemming from ongoing clinical trials and commercial viability. The negative sentiment is underscored by disappointing results from the Phase 1 study of DA-1726 for obesity and challenges in establishing a combination therapy for DA-1241 in metabolic dysfunction-associated steatohepatitis (MASH). Additionally, potential delays in development timelines, smaller than expected market opportunities due to competition and pricing, along with funding constraints, further exacerbate concerns surrounding the company's future prospects.

MTVA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroBo Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroBo Pharmaceuticals Inc (MTVA) Forecast

Analysts have given MTVA a Strong Buy based on their latest research and market trends.

According to 2 analysts, MTVA has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroBo Pharmaceuticals Inc (MTVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.